Envela Corporation (ELA) Tops Q3 Earnings and Revenue Estimates

Envela (NYSEAMERICAN:ELA) shares fell 8.2% to $25.2550 on Friday, after closing at $27.51; the stock traded between $25.49 and $25.2550. Analyst actions included Zacks downgrading to “hold,” B. Riley raising its price target to $18, and Lake Street reiterating a $27 target. Envela reported Q1 EPS of $0.34 on $98.38M revenue.

Boeing (BA) secured a $14.7b contract from Lockheed Martin for PAC-3 Missile Segment Enhancement seeker production. Shares closed at $188.32, down 15.59% over 90 days and 17.32% year-to-date. Analysts debate valuation, with some seeing it as 17.7% overvalued at $188.32 vs. a fair value of $160.01, while a DCF model suggests a fair value of $376.49.

D.A. Davidson analyst Gil Luria raised Micron's (MU) price target to $3,000, citing a 3-5 year growth trajectory driven by AI demand. He argues memory is now a 'mission-critical' component, with long-term supply agreements reducing cyclicality. Micron's Q4 sales surged to $54.23B, with strong guidance and increased long-term commitments. Bank of America also raised its revenue estimates, but differs on valuation. MU trades at 5.94x forward earnings, below sector median.

Cipher Digital (NASDAQ:CIFR) shares rose 0.55% to $14.64 in after-hours trading. Bitfury's Top HoldCo delivered 1.84M shares as part of a forward contract, per SEC filings. Top HoldCo holds 6.2% of Cipher's shares, with V3 Holding and Valerijs Vavilovs owning 13.2%. CIFR's market cap is $6.04B, with a 52-week range of $11.72-$30.14.

Vaxcyte (PCVX) reported positive Phase 3 data for its pneumococcal vaccine and raised $1b via equity and debt. Its shares rose 17.68% in 7 days, 44.12% YTD, and 64.36% in 1 year. Analysts' price targets average $114.78, while intrinsic value models suggest higher potential.

Argus lowered its target price for PTC Therapeutics (PTCT) to $61.00, maintaining a HOLD rating. The company has medium ratings for industry, management, and growth, but low ratings for safety and value.